Nanotechnology-based targeted delivery systems for protein kinase inhibitors in Cancer therapy
Authors:
- Disha MittalDMDisha Mittal
- Karishma NiveriaKNKarishma Niveria
- Anita Kamra VermaAVAnita Kamra Verma
- 21 May 2022
- book chapter
- Published by Elsevier
- p. 747-779
Abstract
No abstract availableThis publication has 140 references indexed in Scilit:
- Carbon Dioxide-Mediated Generation of Hybrid Nanoparticles for Improved Bioavailability of Protein Kinase InhibitorsPharmaceutical Research, 2013
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Multistage nanoparticle delivery system for deep penetration into tumor tissueProceedings of the National Academy of Sciences, 2011
- Mediating Tumor Targeting Efficiency of Nanoparticles Through DesignNano Letters, 2009
- Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancerClinical Therapeutics, 2009
- Receptor tyrosine kinase inhibitors in thyroid cancerBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- A census of human cancer genesNature Reviews Cancer, 2004
- The retinoblastoma protein and cell cycle controlCell, 1995
- Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemiaNature, 1983